Ontogeny, pathology, oncology.
Ontogeny, pathology, oncology.
复制标题
DOI：
10.1387/ijdb.8507567
复制
发表时间：
1993-03
期刊：
影响因子：
--
通讯作者：
V. Papaioannou
中科院分区：
文献类型：
--
作者：
V. Papaioannou
这篇文章追溯了胚胎干细胞用于遗传操作的历史-首先是畸胎瘤干细胞，然后是胚胎干细胞。它包括几十年的研究，调查胚胎正常生长和分化的细胞机制与肿瘤异常生长和分化之间的相似性。畸胎瘤衍生的胚胎癌（EC）干细胞的有限发育潜力与直接来自早期胚胎的胚胎干（ES）细胞所显示的全能性形成对比。从早期尝试在培养的EC细胞中选择突变体，到通过同源重组在ES细胞中靶向基因的巨大成功，发育、遗传和癌症研究的不同方向已经汇聚在一起，为遗传操作开辟了广阔的新领域。
This article traces the history of using embryo-derived stem cells for genetic manipulation--first teratocarcinoma stem cells and then embryonic stem cells. It encompasses several decades of research investigating the similarity between cellular mechanisms of normal growth and differentiation in the embryo and abnormal growth and differentiation in neoplasia. The limited developmental potential of teratocarcinoma-derived, embryonal carcinoma (EC) stem cells is contrasted to the totipotentiality displayed by embryonic stem (ES) cells derived directly from early embryos. From early attempts to select mutants in EC cells in culture to the spectacular success of targeting genes in ES cells by homologous recombination, the different lines of developmental, genetic and cancer research have converged to open vast new areas of possibility in genetic manipulation.